Compare RCKT & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCKT | AKBA |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | 202 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.7M | 248.3M |
| IPO Year | 2014 | 2014 |
| Metric | RCKT | AKBA |
|---|---|---|
| Price | $2.44 | $0.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 6 |
| Target Price | ★ $8.58 | $3.25 |
| AVG Volume (30 Days) | 1.8M | ★ 9.5M |
| Earning Date | 11-24-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 26.37 | ★ 93.94 |
| EPS | ★ 0.66 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $915.60 | N/A |
| P/E Ratio | $3.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.17 | $0.36 |
| 52 Week High | $5.45 | $1.84 |
| Indicator | RCKT | AKBA |
|---|---|---|
| Relative Strength Index (RSI) | 46.44 | 39.44 |
| Support Level | $2.17 | N/A |
| Resistance Level | $2.73 | $1.00 |
| Average True Range (ATR) | 0.19 | 0.08 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 53.98 | 40.47 |
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.